×
Galena Biopharma EBITDA 2010-2024 | SLS
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Galena Biopharma ebitda from 2010 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
View More
Galena Biopharma EBITDA 2010-2024 | SLS
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Galena Biopharma ebitda from 2010 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$173B
Vertex Pharmaceuticals (VRTX)
$129.2B
Bristol Myers Squibb (BMY)
$121.3B
Gilead Sciences (GILD)
$120.8B
CSL (CSLLY)
$91.5B
Regeneron Pharmaceuticals (REGN)
$90.7B
GSK (GSK)
$75.3B
Alnylam Pharmaceuticals (ALNY)
$36.1B
Argenex SE (ARGX)
$35.2B
BioNTech SE (BNTX)
$26.1B
Biogen (BIIB)
$25.1B
Illumina (ILMN)
$24B
BeiGene (BGNE)
$20B
Moderna (MRNA)
$16.5B
Incyte (INCY)
$15.7B
Genmab (GMAB)
$15.4B
Vaxcyte (PCVX)
$12.9B
Insmed (INSM)
$12.8B
BioMarin Pharmaceutical (BMRN)
$12.6B
Bio-Techne Corp (TECH)
$11.9B
Sarepta Therapeutics (SRPT)
$11.3B
Exelixis (EXEL)
$10.3B
Revolution Medicines (RVMD)
$10.2B
QIAGEN (QGEN)
$10.1B
Intra-Cellular Therapies (ITCI)
$9.7B
Exact Sciences (EXAS)
$9.5B
Bio-Rad Laboratories (BIO.B)
$9.4B
Roivant Sciences (ROIV)
$8.7B
Repligen (RGEN)
$7.8B
Ascendis Pharma (ASND)
$7.8B